This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Cianidanol
- DrugBank Accession Number
- DB14086
- Background
An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.
- Type
- Small Molecule
- Groups
- Approved, Withdrawn
- Structure
Structure for Cianidanol (DB14086)
- Weight
- Average: 290.2681
Monoisotopic: 290.07903818 - Chemical Formula
- C15H14O6
- Synonyms
- (+)-catechin
- (+)-Catechol
- (+)-Cyanidan-3-ol
- (+)-Cyanidanol
- (2R,3S)-(+)-Catechin
- (2R,3S)-catechin
- Catechin
- Catechuic acid
- Cianidanol
- Cianidanolum
- D-(+)-Catechin
- d-Catechin
- D-Catechol
- External IDs
- KB 53
- KB-53
- Z 7300
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Cianidanol hydrate Not Available 88191-48-4 OFUMQWOJBVNKLR-NQQJLSKUSA-N - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Slim 2 Powder 0.45 g/100g Oral Bionutrigen Co., Ltd. 2011-09-15 Not applicable US 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Slim 2 Cianidanol (0.45 g/100g) Powder Oral Bionutrigen Co., Ltd. 2011-09-15 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 8R1V1STN48
- CAS number
- 154-23-4
- InChI Key
- PFTAWBLQPZVEMU-DZGCQCFKSA-N
- InChI
- InChI=1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15+/m0/s1
- IUPAC Name
- (2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol
- SMILES
- O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC=C(O)C(O)=C1
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0002780
- KEGG Compound
- C06562
- ChemSpider
- 8711
- BindingDB
- 60836
- 1367177
- ChEBI
- 15600
- ChEMBL
- CHEMBL311498
- ZINC
- ZINC000000119983
- PDBe Ligand
- KXN
- Wikipedia
- Catechin
- PDB Entries
- 3i52 / 4c94 / 4c9i
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Prevention Lung Cancer / Tobacco Use Disorders 1 2 Completed Treatment Cardiac Involvement / Primary Amyloidosis 1 2 Recruiting Other Adenocarcinoma of Prostate / Prostate Cancer 1 2 Terminated Prevention Lung Cancer / Precancerous Conditions / Tobacco Use Disorders 1 2 Terminated Treatment Adenocarcinoma of Colon / Advanced Colorectal Adenomas / Stage I Colon Cancer / Stage II Colon Cancer / Stage III Colon Cancer 1 1 Active Not Recruiting Prevention Cirrhosis of the Liver 1 1 Completed Prevention Barrett's Esophagus 1 1 Completed Treatment Breast Cancer, Stage II / Breast Cancer, Stage IIIB / Estrogen Receptor Negative Breast Cancer / Progesterone Receptor Negative (PR-Negative) Breast Cancer / Stage I Breast Cancer / Stage IIIA Breast Cancer 1 1 Completed Treatment Human Immunodeficiency Virus (HIV) Infections 1 Not Available Completed Prevention Influenza Infection 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder Oral 0.45 g/100g - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.645 mg/mL ALOGPS logP 1.02 ALOGPS logP 1.8 Chemaxon logS -2.6 ALOGPS pKa (Strongest Acidic) 9 Chemaxon pKa (Strongest Basic) -3.3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 5 Chemaxon Polar Surface Area 110.38 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 74 m3·mol-1 Chemaxon Polarizability 27.89 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Drug created at June 17, 2018 22:28 / Updated at June 12, 2020 16:53